<DOC>
	<DOCNO>NCT00688571</DOCNO>
	<brief_summary>This non-randomized , prospective , interventional observational multi-center study design ass long-term clinical performance Medtronic Melodyâ„¢ Transcatheter Pulmonary Valve ( TPV ) post market environment period five year transcatheter implantation patient dysfunctional RVOT conduit . In addition , quality life implant subject assess five year .</brief_summary>
	<brief_title>Melody Transcatheter Pulmonary Valve ( TPV ) Post-Market Surveillance Study</brief_title>
	<detailed_description />
	<mesh_term>Heart Valve Diseases</mesh_term>
	<criteria>Prospective subject complex congenital heart defect palliate RVOT conduit become dysfunctional clinical indication invasive intervention . Prospective subject must meet following inclusion exclusion criterion : Age great equal 5 year age Weight great equal 30 kilogram Existence full ( circumferential ) RVOT conduit equal great 16 mm diameter originally implant Any follow transthoracic echocardiography For patient NYHA Classification II , III , IV : Moderate ( 3+ ) severe ( 4+ ) pulmonary regurgitation , Mean RVOT gradient great equal 35 mmHg . For patient NYHA Classification I : Severe ( 4+ ) pulmonary regurgitation RV dilatation dysfunction , Mean RVOT gradient great equal 40 mmHg . Active endocarditis A major progressive noncardiac disease ( e.g . liver failure , renal failure , cancer ) result life expectancy le one year Patient patient legally give consent guardian unwilling unable provide write informed consent comply followup requirement Obstruction central vein ( include superior inferior vena cava , bilateral iliac vein ) delivery system advanced heart via transvenous approach either femoral vein internal jugular vein Known intravenous drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Pulmonary Valve</keyword>
	<keyword>Congenital Heart Disease</keyword>
</DOC>